SCHEMBL5866830

SCHEMBL5866830

CC(=O)Nc1cccc2cc(/C(=N\O)Nc3cccc(Cl)c3)oc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBR1 P16152 1/20 0.45
AKR1C3 P42330 1/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 5/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GPR35 Q9HC97 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 2/20 0.40
P2RY1 P47900 1/20 0.40
MAOB P27338 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5866832 1.00 CBR1 (0.45) CBR1AKR1C3MEN1KMT2ANPC1
SCHEMBL5867011 0.85 CTPS1 (0.42) CBR1AKR1C3MEN1KMT2ASMN1; SMN2
SCHEMBL5867013 0.85 CTPS1 (0.42) CBR1AKR1C3MEN1KMT2ASMN1; SMN2
SCHEMBL5867078 0.81 CBR1 (0.44) CBR1AKR1C3MEN1KMT2ATP53
SCHEMBL5867088 0.81 CBR1 (0.44) CBR1AKR1C3MEN1KMT2ATP53
SCHEMBL5935550 0.80 HTT (0.53) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL5935552 0.80 HTT (0.53) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL5866940 0.75 KCNQ2 (0.46) CBR1AKR1C3MEN1KMT2ANPC1
SCHEMBL5866939 0.75 KCNQ2 (0.46) CBR1AKR1C3MEN1KMT2ANPC1
SCHEMBL5866919 0.74 MAPT (0.45) MEN1KMT2ANPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148259-B1 Antibacterial agents AMGEN INC. (US) 2006-12-12 US disclosed
US-20060270651-A1 ANTIBACTERIAL AGENTS AMGEN INC. (US) 2006-11-30 US disclosed
US-7053234-B2 Antibacterial agents AMGEN INC. (US) 2006-05-30 US disclosed
US-20040235911-A1 hydroxyamidines; antibiotic resistance TULARIK INC. 2004-11-25 US disclosed
US-6780858-B2 Antibacterial agents TULARIK INC. 2004-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235911-A1 hydroxyamidines; antibiotic resistance HNMT, HDHD5, ABCC1 CBR1 3452/4885AKR1C3 4513/4885MEN1 1387/4885
US-20060270651-A1 ANTIBACTERIAL AGENTS MRPL21, HDHD5, CLPP CBR1 3505/4885AKR1C3 4582/4885MEN1 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.